Influenza vaccine research has reached an exciting new milestone!
Following the success of mRNA technology for COVID-19, Moderna’s mRNA-based influenza vaccine mFLUSIVA® has now received FDA approval for adults aged 50 years and older, marking the first approval of an mRNA flu vaccine in the United States. The development highlights something influenza researchers know well: Influenza viral strains come with a high mutations frequency, and the tools used to study immune responses need to keep pace.
At JPT, we support influenza research with a broad selection of ready-to-use PepMix™ Peptide Pools and individual antigen peptides, as well as custom peptide solutions for emerging or project-specific strains. JPT provides peptide tools to help you look beyond antibody responses and explore cellular immunity.
Explore Influenza-Specific T-cell Responses with PepMix™
Our Influenza PepMix™ portfolio includes antigen-spanning peptide pools covering key proteins and strains from Influenza A and B.
Need to Focus on a Specific Epitope?
Alongside peptide pools, JPT offers individual Influenza antigen peptides for more targeted research. These peptides cover defined influenza epitope seqeunces from different strains and are particularly useful for detailed investigation of individual T-cell epitopes.
A New Influenza Strain? We Can Cover That Too!
If the strain, antigen or sequence you need is not available in our catalog, JPT can manufacture Custom PepMix™ Peptide Pools and individual peptides according to your sequence and specifications. Choose your antigen, peptide design, purity, amount and pooling strategy, and our team can help translate it into the peptide tools needed for your research.
Contact us to discuss a custom Influenza peptide solution.